ABT

Abbott Laboratories
D

ABT

Arincen83/100B

Abbott Laboratories free cash flow 1989–2026

Abbott Laboratories's free cash flow in Q2 FY2026, the three months to 30 June 2026, was 2.89B USD, up 86.9% on the same quarter a year before. Abbott Laboratories's free cash flow over the last twelve months was 8.72B USD, up 28.7% on the twelve months before. In fiscal year 2025 it was 7.40B USD, up 16.4% on the year before.

Last updated 3 Nov 2026 · Next report 28 Jan 2027

Free cash flow

Free cash flow · +14.8% a year over 10 yearsFree cash flow margin

Growth

Fiscal yearPeriod endingFree cash flowGrowthFree cash flow marginOperating cash flowCapital expenditureFree cash flow per share
TTM30 Jun 20268.72B+28.71%18.08%9.91B-1.19B5.00
FY202531 Dec 20257.40B+16.44%16.68%9.57B-2.17B4.23
FY202431 Dec 20246.35B+25.54%15.14%8.56B-2.21B3.63
FY202331 Dec 20235.06B-35.17%12.61%7.26B-2.20B2.89
FY202231 Dec 20227.80B-9.76%17.88%9.58B-1.78B4.42
FY202131 Dec 20218.65B+51.08%20.08%10.53B-1.89B4.83
FY202031 Dec 20205.72B+27.26%16.54%7.90B-2.18B3.20
FY201931 Dec 20194.50B-8.32%14.10%6.14B-1.64B2.53
FY201831 Dec 20184.91B+10.62%16.04%6.30B-1.39B2.77
FY201731 Dec 20174.44B+113.02%16.19%5.57B-1.14B2.54
FY201631 Dec 20162.08B+12.18%9.98%3.20B-1.12B1.40
FY201531 Dec 20151.86B-28.56%9.10%2.97B-1.11B1.23
FY201431 Dec 20142.60B+19.23%12.83%3.68B-1.08B1.70
FY201331 Dec 20132.18B-71.02%9.97%3.32B-1.15B1.38
FY201231 Dec 20127.52B+0.54%18.86%9.31B-1.80B4.72
FY201131 Dec 20117.48B-3.14%19.25%8.97B-1.49B4.77
FY201031 Dec 20107.72B+24.81%21.95%8.74B-1.02B4.96
FY200931 Dec 20096.19B+2.14%20.11%7.28B-1.09B3.98
FY200831 Dec 20086.06B+71.69%20.51%7.34B-1.29B3.88
FY200731 Dec 20073.53B-11.62%13.61%5.18B-1.66B2.26
FY200631 Dec 20063.99B+0.62%17.76%5.33B-1.34B2.60
FY200531 Dec 20053.97B+27.30%17.76%5.17B-1.21B2.54
FY200431 Dec 20043.12B+24.67%15.83%4.41B-1.29B1.98
FY200331 Dec 20032.50B-13.40%12.70%3.75B-1.25B1.59
FY200231 Dec 20022.89B+20.12%16.32%4.18B-1.30B1.83
FY200131 Dec 20012.40B+16.45%14.76%3.57B-1.16B1.53
FY200031 Dec 20002.06B+5.81%15.01%3.10B-1.04B1.32
FY199931 Dec 19991.95B+30.88%14.80%2.94B-987.10M1.25
FY199831 Dec 19981.49B+5.01%11.94%2.73B-1.24B0.95
FY199731 Dec 19971.42B-0.97%11.94%2.63B-1.21B0.90
FY199631 Dec 19961.43B-27.09%13.01%2.38B-949.00M0.91
FY199531 Dec 19951.97B-11.15%19.63%1.97B0.001.23
FY199431 Dec 19942.21B+19.78%24.16%2.21B0.001.36
FY199331 Dec 19931.85B+383.99%21.97%1.85B0.001.11
FY199231 Dec 1992381.60M-44.10%4.86%1.39B-1.01B0.23
FY199131 Dec 1991682.60M+22.00%9.93%1.45B-770.60M0.40
FY199031 Dec 1990559.50M+44.65%9.08%1.20B-641.40M0.32
FY198931 Dec 1989386.80M—7.19%959.90M-573.10M0.22

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Stock buybacks,Cash flow

Common questions about Abbott Laboratories's free cash flow

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.